Medolife Rx Announces Pre-Clinical Results on Drug Candidate Escozine Showing Efficacy in Eliminating Cell Lines in Ovarian and Bladder Cancer
March 23, 2021 09:00 ET
|
Quanta, Inc.
BURBANK, Calif., March 23, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product...
Medolife Rx Announces Positive Results in Clinical Safety Study on Its Polarized Drug Candidate for the Treatment of COVID-19
March 18, 2021 08:30 ET
|
Quanta, Inc.
BURBANK, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product...
MedolifeRx Announces Results From Efficacy Test on Polarization Technology Showing 497 Percent Increase in Efficacy of API When Polarized
March 16, 2021 09:00 ET
|
Quanta, Inc.
BURBANK, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing and consumer product...
Medolife Rx Announces Preclinical Trial Results From Toxicity Study on Lead Drug Candidate
March 09, 2021 09:00 ET
|
Quanta, Inc.
BURBANK, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc. ("Medolife"), a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today preclinical...
Medolife Rx Announces CMW Media as Strategic Communications Firm
March 04, 2021 09:00 ET
|
Quanta, Inc.
BURBANK, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Medolife Rx, Inc., ("Medolife") a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), today announced that the Company...
Quanta Announces “Town Hall” Style Shareholder Update for June 15, 2020 at 1:30 PM ET
June 11, 2020 09:01 ET
|
Quanta, Inc.
BURBANK, CA, June 11, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Quanta, Inc. (OTCPK:QNTA), an applied sciences company based on a quantum biology platform that significantly boosts the potency...